Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mizuho Medy Co.,Ltd. (4595.T)
Tosu, JP
Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While its primary operations are in Japan, the company maintains an international presence through import and export activities, extending its reach to countries including the United States, Belgium, Finland, the Netherlands, Taiwan, and Thailand. Its extensive product lineup includes a wide array of immunoassay test kits designed for detecting pathogens such as influenza viruses, RS virus, human metapneumovirus, Streptococcus pneumoniae, Legionella, Mycoplasma pneumoniae, adenovirus, rotavirus, norovirus, and Group A streptococcus. Additionally, Mizuho Medy offers kits for pregnancy, ovulation, and fecal occult blood screening. The company also provides advanced tools like gene analysis instruments and specialized diagnostic kits for SARS-CoV-2 detection and Mycoplasma pneumoniae nucleic acid analysis.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.51% | +1.81% | -4.34% | -6.44% | +9.08% | +0.64% | +16.68% | +68.72% | +32.72% | +471.84% | +461.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-1.5% Q1'26: -16.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-9.2% Q1'26: -22.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+13.0% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+41.3% ★ Q1'26: +34.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+42.8% ★ Q1'26: +38.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.43B
est: 6.50B (-1.2%)
|
6.43B
est: 6.70B (-4.1%)
|
4.20B
est: 4.25B (-1.2%)
|
12.89B
est: 13.06B (-1.3%)
|
17.58B
est: 17.10B (+2.8%)
|
10.99B
est: 11.20B (-1.9%)
|
11.43B
est: 10.50B (+8.8%)
|
11.26B
est: 11.35B (-0.8%)
|
11.40B
11.40B – 11.40B
+0.4% YoY
|
11.90B
11.90B – 11.90B
+4.4% YoY
|
12.40B
12.40B – 12.40B
+4.2% YoY
|
| EBITDA |
1.32B
est: 2.94B (-55.2%)
|
1.28B
est: 3.03B (-57.9%)
|
610.07M
est: 1.93B (-68.3%)
|
6.87B
est: 5.91B (+16.2%)
|
11.26B
est: 7.74B (+45.5%)
|
5.40B
est: 5.07B (+6.4%)
|
5.10B
est: 5.35B (-4.6%)
|
4.91B
est: 5.78B (-15.0%)
|
5.81B
5.81B – 5.81B
+0.4% YoY
|
6.06B
6.06B – 6.06B
+4.4% YoY
|
6.32B
6.32B – 6.32B
+4.2% YoY
|
| EBIT |
1.22B
est: 2.81B (-56.5%)
|
1.11B
est: 2.89B (-61.6%)
|
416.22M
est: 1.84B (-77.3%)
|
6.70B
est: 5.64B (+18.8%)
|
11.10B
est: 7.38B (+50.5%)
|
5.15B
est: 4.83B (+6.6%)
|
4.92B
est: 5.17B (-4.9%)
|
4.65B
est: 5.59B (-16.9%)
|
5.62B
5.62B – 5.62B
+0.4% YoY
|
5.86B
5.86B – 5.86B
+4.4% YoY
|
6.11B
6.11B – 6.11B
+4.2% YoY
|
| Net Income |
919.21M
est: 949.58M (-3.2%)
|
874.34M
est: 949.58M (-7.9%)
|
306.35M
est: 149.53M (+104.9%)
|
4.82B
est: 4.59B (+5.0%)
|
7.84B
est: 7.42B (+5.6%)
|
3.77B
est: 3.95B (-4.4%)
|
3.77B
est: 3.04B (+24.1%)
|
3.43B
est: 3.44B (-0.5%)
|
3.23B
3.23B – 3.23B
-6.1% YoY
|
3.37B
3.37B – 3.37B
+4.3% YoY
|
3.51B
3.51B – 3.51B
+4.2% YoY
|
| SGA |
2.63B
est: 1.48B (+77.1%)
|
2.71B
est: 1.53B (+77.3%)
|
1.77B
est: 970.01M (+82.9%)
|
2.32B
est: 2.98B (-22.2%)
|
2.34B
est: 3.90B (-40.1%)
|
2.20B
est: 2.55B (-13.7%)
|
2.34B
est: 1.94B (+20.6%)
|
2.31B
est: 2.10B (+10.3%)
|
2.10B
2.10B – 2.10B
+0.4% YoY
|
2.20B
2.20B – 2.20B
+4.4% YoY
|
2.29B
2.29B – 2.29B
+4.2% YoY
|
| EPS |
48.25
est: 49.85 (-3.2%)
|
45.90
est: 49.85 (-7.9%)
|
16.08
est: 7.85 (+104.8%)
|
252.86
est: 240.85 (+5.0%)
|
411.47
est: 389.50 (+5.6%)
|
198.13
est: 207.35 (-4.4%)
|
198.07
est: 159.60 (+24.1%)
|
179.80
est: 180.70 (-0.5%)
|
169.60
169.60 – 169.60
-6.1% YoY
|
176.90
176.90 – 176.90
+4.3% YoY
|
184.30
184.30 – 184.30
+4.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Small-Cap Equity Factor ETF ISCF | 0.07% | 447.8K | 0.24% |
| 2 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.04% | 160.8K | 0.58% |
| 3 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.03% | 124.7K | 0.48% |
| 4 | WisdomTree International Equity Fund DWM | 0.02% | 103.6K | 0.48% |
| 5 | Dimensional - International Small Cap ETF DFIS | 0.00% | 241.2K | 0.39% |
| 6 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 255.8K | 0.22% |
| 7 | Avantis International Small Cap Value ETF AVDV | 0.00% | 240.9K | 0.36% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 120.5K | 0.28% |
| 9 | Dimensional International Sustainability Core 1 ETF DFSI | 0.00% | 11.1K | 0.24% |
| 10 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | 170.6K | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fuminari Karakawa | Chairman of the Board & President | — | male |
| Kazuhiro Ichimaru | GM of Intellectual Property & Manufacturing Department and Director | — | male |
| Kenji Narahara | GM of Development Department & Director | — | male |
| Takahiro Furuno | Executive Officer & Manager of Manufacturing Department | — | — |
| Toshio Kamihara | GM of Sales Division & Overseas Business Department and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4595.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
